Published in Neurology on May 04, 2011
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology (2014) 3.27
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol (2015) 2.23
Fingolimod after natalizumab and the risk of short-term relapse. Neurology (2014) 1.96
Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology (2012) 1.63
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS. Neurology (2015) 1.55
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol (2014) 1.20
Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology (2014) 1.18
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. J Neurol (2012) 1.11
An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations. Patient Prefer Adherence (2015) 0.94
Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis. PLoS One (2012) 0.93
Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol (2015) 0.92
Monoclonal antibodies in treatment of multiple sclerosis. Clin Exp Immunol (2014) 0.91
Natalizumab therapy for multiple sclerosis. Neurotherapeutics (2013) 0.89
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? World J Clin Cases (2015) 0.88
Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis. J Cent Nerv Syst Dis (2014) 0.87
Best practice in the use of natalizumab in multiple sclerosis. Ther Adv Neurol Disord (2013) 0.85
Bridging, switching or drug holidays - how to treat a patient who stops natalizumab? Ther Clin Risk Manag (2013) 0.85
Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities. Mult Scler Int (2015) 0.85
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol (2013) 0.83
What happens when natalizumab therapy is stopped? Expert Rev Neurother (2011) 0.82
Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up. Neurol Sci (2013) 0.81
How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis? Front Neurol (2013) 0.81
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. J Neurol (2014) 0.81
Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient. J Neurol (2013) 0.80
From injection therapies to natalizumab: views on the treatment of multiple sclerosis. Ther Adv Neurol Disord (2012) 0.80
Multiple sclerosis reactivation postfingolimod cessation: is it IRIS? BMJ Case Rep (2014) 0.80
Monoclonal antibodies as disease modifying therapy in multiple sclerosis. Curr Neurol Neurosci Rep (2013) 0.79
Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers. Neurol Ther (2015) 0.78
Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort. Neurol Neuroimmunol Neuroinflamm (2016) 0.78
Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life. Patient Relat Outcome Meas (2014) 0.77
Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord (2015) 0.77
Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report. BMC Neurol (2015) 0.77
Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions. BMC Neurol (2014) 0.77
New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come. J Cent Nerv Syst Dis (2012) 0.77
Extended interval dosing of natalizumab: a two-center, 7-year experience. Ther Adv Neurol Disord (2014) 0.77
Pregnancy outcomes in Lebanese women with multiple sclerosis (the LeMS study): a prospective multicentre study. BMJ Open (2016) 0.76
Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β. BMC Neurol (2014) 0.76
Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis. Clin Ophthalmol (2012) 0.76
Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis. CNS Drugs (2015) 0.76
Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Ther Adv Neurol Disord (2015) 0.76
High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study. Neurol Ther (2016) 0.76
Recurrence of disease activity after repeated Natalizumab withdrawals. Neurol Sci (2014) 0.75
CD4 cell response to interval therapy with natalizumab. Ann Clin Transl Neurol (2015) 0.75
Update on immunopathogenesis and immunotherapy in multiple sclerosis. Immunotargets Ther (2013) 0.75
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 0.75
Treatment decisions in multiple sclerosis - insights from real-world observational studies. Nat Rev Neurol (2017) 0.75
Severe inflammatory disease activity 14 months after cessation of Natalizumab in a patient with Leber's optic neuropathy and multiple sclerosis - a case report. BMC Neurol (2016) 0.75
Interruption of natalizumab therapy for multiple sclerosis: what are the risks? Neurology (2011) 0.75
Multiple sclerosis: Natalizumab to fingolimod--the washout whitewash. Nat Rev Neurol (2014) 0.75
Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation. Brain Behav (2017) 0.75
Disability Progression After Switching from Natalizumab to Fingolimod or Interferon Beta/Glatiramer Acetate Therapies: A NARCOMS Analysis. Int J MS Care (2016) 0.75
Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring. BMC Neurol (2014) 0.75
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor). BMC Neurol (2015) 0.75
Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients. J Neurol (2016) 0.75
Some recent advances in multiple sclerosis. J Neurol (2016) 0.75
Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome. Neurol Neuroimmunol Neuroinflamm (2017) 0.75
Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors. J Neurol (2016) 0.75
Neurological safety of fingolimod: An updated review. Clin Exp Neuroimmunol (2017) 0.75
Transient autoimmune hyperthyroidism following the withdrawal of Natalizumab in patients with multiple sclerosis. Neurol Sci (2013) 0.75
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol (1996) 10.39
Hydroxyproline arabinosides in the plant kingdom. Plant Physiol (1971) 4.67
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
The 5th National Audit Project (NAP5) on accidental awareness during general anaesthesia: summary of main findings and risk factors. Anaesthesia (2014) 4.07
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler (1999) 3.71
Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology (2011) 3.62
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Genetic heterogeneity and mitochondrial DNA heteroplasmy in Leber's hereditary optic neuropathy. J Med Genet (1989) 3.25
The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain (1987) 3.15
Central nervous system sarcoidosis--diagnosis and management. QJM (1999) 3.11
Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol (1995) 3.06
A microsatellite genetic linkage map for zebrafish (Danio rerio). Nat Genet (1998) 3.06
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain (2000) 2.84
Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol (2005) 2.67
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain (2008) 2.67
Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol (1984) 2.64
Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain (1992) 2.62
Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies. Ann Neurol (1993) 2.56
Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology (1999) 2.54
Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain (1996) 2.54
Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol (1985) 2.50
Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology (2000) 2.47
Diffusion tensor imaging can detect and quantify corticospinal tract degeneration after stroke. J Neurol Neurosurg Psychiatry (2000) 2.44
The persistent vegetative state. BMJ (1995) 2.35
MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology (2010) 2.33
Management of acute optic neuritis. Lancet (2002) 2.33
Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology (2008) 2.29
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology (2011) 2.26
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Hydroxyproline heterooligosaccharides in Chlamydomonas. Science (1972) 2.12
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology (2008) 2.11
A genetic linkage map of the laboratory rat, Rattus norvegicus. Nat Genet (1995) 2.10
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology (2008) 2.07
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry (1991) 2.05
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology (2010) 2.04
Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry (1996) 2.02
The anaesthetic classification of caesarean sections. Anaesthesia (1996) 2.02
Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain (2002) 2.01
Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain (1990) 2.00
Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. Brain (1989) 2.00
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain (1998) 1.99
Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol (1998) 1.97
The chemical composition of the cell wall of Chlamydomonas gymnogama and the concept of a plant cell wall protein. J Cell Biol (1974) 1.95
Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci U S A (1990) 1.93
Self glycolipids as T-cell autoantigens. Eur J Immunol (1999) 1.93
Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology (2009) 1.93
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev (2001) 1.88
Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology (1993) 1.87
A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology (2002) 1.86
Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis. Lancet (1991) 1.86
The 5th National Audit Project (NAP5) on accidental awareness during general anaesthesia: patient experiences, human factors, sedation, consent and medicolegal issues. Anaesthesia (2014) 1.85
Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology (2011) 1.83
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology (1999) 1.82
Neuropathological abnormalities of the corpus callosum in schizophrenia: a diffusion tensor imaging study. J Neurol Neurosurg Psychiatry (2000) 1.81
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80
Primary progressive multiple sclerosis. Brain (1997) 1.80
Precise estimate of fundamental in-vivo MT parameters in human brain in clinically feasible times. Magn Reson Imaging (2002) 1.80
Eight-year follow-up study of brain atrophy in patients with MS. Neurology (2002) 1.78
Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology (2009) 1.78
A multicenter measurement of magnetization transfer ratio in normal white matter. J Magn Reson Imaging (1999) 1.76
Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology (2011) 1.75
Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest (1993) 1.73
Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J Neurochem (1999) 1.73
Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology (2004) 1.73
The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity (2000) 1.72
Comparison of propofol deep sedation versus moderate sedation during endosonography. Dig Dis Sci (2010) 1.72
Inequalities in usage of a public bicycle sharing scheme: socio-demographic predictors of uptake and usage of the London (UK) cycle hire scheme. Prev Med (2012) 1.71
Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain (1996) 1.69
Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain (1994) 1.68
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
A reference cross DNA panel for zebrafish (Danio rerio) anchored with simple sequence length polymorphisms. Development (1996) 1.67
Audit: the use of radiotherapy for NSCLC in the UK. Clin Oncol (R Coll Radiol) (1993) 1.67
Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol (1997) 1.66
Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol (2000) 1.66
The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler (2009) 1.65
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler (2009) 1.65
Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol (1996) 1.64
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol (2008) 1.63
Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology (1998) 1.62
Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology (2002) 1.61
Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology (1990) 1.61
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology (1997) 1.60
Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology (1994) 1.60
Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry (2005) 1.59